Schizophrenia Research
Volume 81, Issue 2 , Pages 139-143, 31 January 2006

Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America☆

  • Siegfried Kasper

      Affiliations

    • Department of General Psychiatry, Medical University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 1 40400 3568; fax: +43 1 40400 3099.
    • ,
  • Amanda J. Lowry

      Affiliations

    • Clinical Outcomes and Research Institute, Eli Lilly Australia Pty Limited, Australia
    • ,
  • Andrew Hodge

      Affiliations

    • Clinical Outcomes and Research Institute, Eli Lilly Australia Pty Limited, Australia
    • ,
  • Istvan Bitter

      Affiliations

    • Eli Lilly Regional Operations, Vienna, Austria
    • Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    • ,
  • Martin Dossenbach

      Affiliations

    • Eli Lilly Ges.m.b.H (Austria)

Received 27 April 2004; received in revised form 6 July 2005; accepted 6 July 2005.

Abstract 

The point prevalence of Tardive Dyskinesia (TD) in schizophrenia outpatients (n=6981) participating in a study of health outcomes was 8.9%. Duration of diagnosis, age, and prior use of typical antipsychotics were diagnostic indicators of TD in this population, with male sex further increasing risk. This study provides new data in a non-Western population with a unique regional geography comparison.

Keywords: Schizophrenia, Tardive dyskinesia, Prevalence, Risk factor, Antipsychotic, Africa, Asia, Mid-Eastern

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Part of these data have been presented in poster format at the 16th Congress of the European College of Neuropsychopharmacology (ECNP) and the 42nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

PII: S0920-9964(05)00294-X

doi:10.1016/j.schres.2005.07.032

Schizophrenia Research
Volume 81, Issue 2 , Pages 139-143, 31 January 2006

Article Tools

* Image Usage & Resolution